Login / Signup

Use of next-generation sequencing to detect mutations associated with antiviral drug resistance in cytomegalovirus.

Nicholas T StreckMark J EspyMatthew J FerberEric W KleeRaymund R RazonableDimitri GonzalezChalom SayadaPhillip R HeatonSunwen ChouMatthew J Binnicker
Published in: Journal of clinical microbiology (2023)
Cytomegalovirus (CMV) is a significant cause of morbidity and mortality among immunocompromised hosts, including transplant recipients. Antiviral prophylaxis or treatment is used to reduce the incidence of CMV disease in this patient population; however, there is concern about increasing antiviral resistance. Detection of antiviral resistance in CMV was traditionally accomplished using Sanger sequencing of UL54 and UL97 genes, in which specific mutations may result in reduced antiviral activity. In this study, a novel next-generation sequencing (NGS) method was developed and validated to detect mutations in UL54 / UL97 associated with antiviral resistance. Plasma samples ( n = 27) submitted for antiviral resistance testing by Sanger sequencing were also analyzed using the NGS method. When compared to Sanger sequencing, the NGS assay demonstrated 100% (27/27) overall agreement for determining antiviral resistance/susceptibility and 88% (22/25) agreement at the level of resistance-associated mutations. The limit of detection of the NGS method was determined to be 500 IU/mL, and the lower threshold for detecting mutations associated with resistance was established at 15%. The NGS assay represents a novel laboratory tool that assists healthcare providers in treating patients who are infected with CMV harboring resistance-associated mutations and who may benefit from tailored antiviral therapy.
Keyphrases
  • healthcare
  • herpes simplex virus
  • single cell
  • stem cells
  • end stage renal disease
  • risk factors
  • case report
  • copy number
  • peritoneal dialysis
  • quantum dots
  • patient reported outcomes
  • real time pcr
  • circulating tumor